Targeted Molecular Imaging as a Biomarker in Urologic Oncology - 22/11/22
Résumé |
Urologic malignancies constitute a large portion of annually diagnosed cancers. Timely diagnosis, accurate staging, and assessment of tumor heterogeneity are essential to devising the best treatment strategy for individual patients. The high sensitivity of molecular imaging allows for early and sensitive detection of lesions that were not readily detectable using conventional imaging techniques. Moreover, molecular imaging enables the interrogation of molecular processes used in targeted cancer therapies and predicts cancer response to treatment. Here we review the current advancements in molecular imaging of urologic cancers, including prostatic, vesical, renal testicular, and ureteral cancers.
Le texte complet de cet article est disponible en PDF.Keywords : Molecular imaging, Radiopharmaceuticals, Urologic malignancies, Imaging biomarker, PET, SPECT, Hyperpolarized MR
Plan
Vol 50 - N° 1
P. 115-131 - février 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?